Teva Pharmaceutical Industries (BSP:T1EV34) Research & Development: R$5,344 Mil (TTM As of Mar. 2026)


BSP:T1EV34 Teva Pharmaceutical Industries Ltd BSP:T1EV34
60 GF Score
Price R$85.99
GF Value R$53.50
! 4 Warning Signs
View Full Analysis

What is Teva Pharmaceutical Industries Research & Development?

Teva Pharmaceutical Industries BSP:T1EV34 60 Research & Development is R$5,344 Mil as of Mar. 2026. GuruFocus rates BSP:T1EV34 with a GF Score™ of 60/100 and a GF Value™ of R$53.50. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Teva Pharmaceutical Industries's Research & Development for the three months ended in Mar. 2026 was R$1,161 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was R$5,344 Mil.

Teva Pharmaceutical Industries  (BSP:T1EV34) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Teva Pharmaceutical Industries Research & Development Related Terms

Teva Pharmaceutical Industries Research & Development Historical Data

* Premium members only.

The historical data trend for Teva Pharmaceutical Industries's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teva Pharmaceutical Industries Research & Development Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,468.29 4,395.65 4,669.51 6,088.80 5,526.62

Teva Pharmaceutical Industries Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,422.25 1,353.18 1,372.93 1,456.67 1,160.97
BSP:T1EV34
60GF Score
Teva Pharmaceutical Industries Ltd BSP:T1EV34
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Teva Pharmaceutical Industries Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$5,344 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of R$5,344 Mil mean?
Teva Pharmaceutical Industries (BSP:T1EV34) has a Research & Development of R$5,344 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Teva Pharmaceutical Industries and its competitors.
Is Teva Pharmaceutical Industries' Research & Development too high?
Teva Pharmaceutical Industries' current Research & Development is R$5,344 Mil. Overall, Teva Pharmaceutical Industries has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' Research & Development compare to ZTS and UTHR?
Teva Pharmaceutical Industries' Research & Development of R$5,344 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Teva Pharmaceutical Industries and its competitors. Teva Pharmaceutical Industries's current Research & Development is R$5,344 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Teva Pharmaceutical Industries (BSP:T1EV34) has a current Research & Development of R$5,344 Mil. The stock's GF Value™ is R$53.50, compared to a current price of R$85.99 — trading 60.7% above its estimated fair value. The current Research & Development is R$5,344 Mil. Teva Pharmaceutical Industries' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Teva Pharmaceutical Industries (BSP:T1EV34), the current Research & Development is R$5,344 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Teva Pharmaceutical Industries (BSP:T1EV34) Overvalued in 2026?

Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued. The current stock price of R$85.99 is trading 60.7% above its estimated GF Value™ of R$53.50.

Key valuation signals for BSP:T1EV34:

  • Research & Development: R$5,344 Mil
  • GF Value™: R$53.50 vs. price of R$85.99 (60.7% above fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the BSP:T1EV34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Teva Pharmaceutical Industries Business Description

Address 124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
60GF Score

Get the complete analysis for BSP:T1EV34

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$85.99
Price
R$53.50
GF Value